Kenija - angļu - Pharmacy and Poisons Board

ddd limited 94 rickmansworth road watford hertfordshire wd18 - strong ammonia solution aromatic ammonia solution… - cream - 0.100 % w/w 6.040 % w/w 0.494 % w/w - other dermatological preparations

Kenija - angļu - Pharmacy and Poisons Board

ddd limited 94 rickmansworth road watford hertfordshire wd18 - activated dimeticone - oral drops - 42.00 mg/5 ml - drugs for functional gastrointestinal disorders

Kenija - angļu - Pharmacy and Poisons Board

ddd limited 94 rickmansworth road watford hertfordshire wd18 - lidocaine hydrochloride cetylpyridinium chloride - dental gel - 0.33 % w/w 0.10 % w/w - other stomatological preparations for local oral

Kenija - angļu - Pharmacy and Poisons Board

ddd limited 94 rickmansworth road watford hertfordshire wd18 - lidocaine hydrochloride aminoacridine… - gel - 0.66 % w/w 0.05 % w/w - other stomatological preparations for local oral

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen tablets are indicated for: the relief of the signs and symptoms of: the management of: naproxen tablets are contraindicated in the following patients: risk summary use of nsaids, including naproxen, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including naproxen, in pregnant women starting at 30 weeks of gestation (third trimester). there are no adequate and well-controlled studies of naproxen in pregnant women. data from observational studies regarding potential embryofetal risks of nsaid use in women in the first or second trimesters of pregnancy are inconclusive. in the general u.s. population, all clinically recognized pregnancies, regardless of drug exposure, have a background rate of 2% to 4% for major malformations, and 15% to 20% for pregnancy loss. in animal reproduction studies in rats, rabbits, and mice no evidence of teratogenicity or fetal harm when naproxen was administered during the period of organ

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

bryant ranch prepack - desvenlafaxine succinate (unii: zb22enf0xr) (desvenlafaxine - unii:ng99554anw) - desvenlafaxine extended-release tablets are indicated for the treatment of adults with major depressive disorder (mdd) [see clinical studies (14) ] . there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for antidepressants at 1-844-405-6185. there are no published studies on desvenlafaxine extended-release tablets in pregnant women; however published epidemiologic studies of pregnant women exposed to venlafaxine, the parent compound, have not reported a clear association with adverse developmental outcomes (see data) . there are risks associated with untreated depression in pregnancy and with exposure to snris and ssris, including desvenlafaxine extended-release tablets, during pregnancy (see clinical considerations). in reproductive developmental studies in rats and rabbits treated with desvenlafaxine succinate, there was no evidence of

Īrija - angļu - HPRA (Health Products Regulatory Authority)

d.d.d. limited - aminacrine hydrochloride; lignocaine hydrochloride - oromucosal gel - 0.66 %w/w +0.05 percent weight/weight - anesthetics for topical use; lidocaine; acridine derivatives

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

remedyrepack inc. - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam oral solution is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 1 month of age and older with epilepsy. levetiracetam oral solution is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. levetiracetam oral solution is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. levetiracetam oral solution is contraindicated in patients with a hypersensitivity to levetiracetam. reactions have included anaphylaxis and angioedema [see warnings and precautions ( 5.4)]. levetiracetam blood levels may decrease during pregnancy [see warnings and precautions ( 5.10) ]. pregnancy category c there are no adequate and we

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

globus medical australia pty ltd - 16101 - fixation device, internal, screw - the zyfuse? facet fixation system is intended to stabilize the spine as an aid to fusion through bilateral immobilization of the facet joints, with or without bone graft, at single or multiple levels, from l1 to s1. for transfacet fixation, the screws are inserted posteriorly through the superior side of the facet, across the facet joint, and into the pedicle. for translaminar facet fixation, the screws are inserted posteriorly through the lateral aspect of the spinous process, through the lamina, through the superior side of the facet, across the facet joint, and into the pedicle. the zyfuse? facet fixation system is indicated for treatment of any or all of the following: pseudoarthrosis and failed previous fusions which are symptomatic or which may cause secondary instability or deformity; spondylolisthesis; spondylolysis; degenerative disc disease (ddd) as defined by neck and/or back pain of discogenic origin as confirmed by radiographic studies; degeneration of the facets with instability and trauma inclu

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd - 48165 - lumbar total disc replacement prosthesis - intended for use in skeletally mature patients undergoing primary surgery for treatment of symptomatic degenerative disc disease (ddd) of the lumbar spine at any one level or two adjacent levels between l3 through s1, who have not responded to at least 6 months of non-operative, conservative management.